Back to Studies

IMPAACT 2039A

Phase I Study of the Safety and Immunogenicity of HIVconsvX Vaccines and the Safety and Pharmacokinetics of Broadly Neutralizing Antibodies in Children Living with HIV

Study Status

In Development

DAIDS Number

39194

IND Number

031,905

Clinical Trials Link

TBD

Primary Protocol Team Members

Mark Cotton Study Chair

Avy Violari Study Vice-Chair

Elizabeth (Betsy) McFarland Study Vice-Chair

Anne Coletti Clinical Research Manager

Sarah Buisson Clinical Research Manager

Elizabeth Kjeldsen Clinical Research Manager

Hans Spiegel DAIDS Medical Officer

Sai Majji NICHD Medical Officer

Loading study documents...

Loading study sites...

Loading study protocol team...

Loading study press...

Loading study publications/presentations...